Core Viewpoint - A securities class action lawsuit has been filed against SelectQuote, Inc. for allegedly misleading investors regarding its business practices and compliance with regulations [1][2]. Allegations - SelectQuote allegedly steered Medicare beneficiaries to insurance plans that provided the highest commissions rather than those best suited for customers [7]. - The company is accused of failing to provide unbiased Medicare Advantage comparisons as claimed [7]. - SelectQuote reportedly accepted illegal kickbacks to favor certain insurers, limiting competition [7]. - The company is alleged to have been non-compliant with laws, regulations, and contracts, exposing it to regulatory and legal risks, including under the False Claims Act [7]. - Positive statements made by SelectQuote about its business and prospects were misleading and lacked a reasonable basis [7]. Impact on Investors - Following the announcement by the U.S. Department of Justice on May 1, 2025, SelectQuote's stock price fell by 19.2%, decreasing by $0.61 to close at $2.56 per share [3]. Legal Context - Investors have until October 10, 2025, to seek appointment as lead plaintiff in the case [4]. - The law firm representing the investors, Wolf Haldenstein Adler Freeman & Herz LLP, has over 125 years of experience in securities litigation [4]. Key Events - The U.S. Department of Justice filed a False Claims Act complaint against SelectQuote, alleging that from 2016 to 2021, the company received tens of millions of dollars in illegal kickbacks from insurers [7]. - The DOJ also alleged that SelectQuote conspired with major insurers to discriminate against less profitable beneficiaries, including those with disabilities [7]. - The DOJ concluded that SelectQuote falsely claimed to provide "unbiased coverage comparisons" while steering customers toward higher-paying plans [7].

Core Points - Holzer & Holzer, LLC is investigating Soleno Therapeutics, Inc. for potential violations of federal securities laws following a report by Scorpion Capital that questioned the credibility of the company's phase 3 clinical trials for its drug VYKAT™ XR [1] - The report from Scorpion Capital highlighted numerous problems with the clinical trials and withdrawal studies, leading to a decline in Soleno Therapeutics' stock price [1] Company Overview - Soleno Therapeutics, Inc. is publicly traded on NASDAQ under the ticker SLNO and is focused on developing treatments, including VYKAT™ XR [1] - The company is currently facing scrutiny regarding its compliance with securities laws due to allegations of issues in its clinical trial processes [1] Legal Context - Holzer & Holzer, LLC is a law firm specializing in securities litigation and has a history of representing shareholders in class action lawsuits [3] - The firm has been recognized as a top-rated securities litigation law firm for multiple years and has recovered significant amounts for investors affected by corporate misconduct [3]

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the strength and sustainability of Flywire's revenue growth was overstated; (2 ...

Core Viewpoint - A class action securities lawsuit has been filed against Vestis Corporation, alleging securities fraud that negatively impacted investors between May 2, 2024, and May 6, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Vestis provided misleading positive statements while concealing adverse facts about its business growth capabilities [2]. - Vestis announced disappointing financial results for Q2 2025, withdrawing its revenue guidance for the full fiscal year and providing lower-than-expected guidance for Q3 2025 [2]. - Following the announcement, Vestis' stock price plummeted from $8.71 per share on May 6, 2025, to $5.44 per share on May 7, 2025, marking a decline of approximately 37.54% in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until August 8, 2025, to request appointment as lead plaintiff in the lawsuit [3]. - Participation in the lawsuit does not require any out-of-pocket costs or fees for class members [3]. Group 3: Firm Background - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Insights - Holzer & Holzer, LLC is investigating whether BellRing Brands, Inc. complied with federal securities laws following the announcement of its third quarter 2025 financial results [1] - The financial results revealed a decrease in net earnings compared to the prior year and a narrowed fiscal year 2025 outlook for net sales and Adjusted EBITDA [1] - Following the announcement, the stock price of BellRing Brands experienced a decline [1] Financial Performance - BellRing Brands reported a decrease in net earnings for the third quarter of 2025 compared to the same period in the previous year [1] - The company has adjusted its fiscal year 2025 outlook, indicating a more conservative estimate for net sales and Adjusted EBITDA [1]

NEW YORK, Aug. 5, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Neogen Corporation ("Neogen Corporation" or the "Company") (NASDAQ: NEOG) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Neogen Corporation investors who were adversely affected by alleged securities fraud between January 5, 2023 and June 3, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/neogen-corp ...

ATLANTA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Fluor Corporation ("Fluor" or the "Company") (NYSE: FLR) complied with federal securities laws. On August 1, 2025, Fluor released its second quarter 2025 financial results, revealing declines year over year in revenue, adjusted EPS, and adjusted EBITDA, which was attributed to "three long-standing infrastructure projects and a shift in expected capital spending from some clients." Following this news, the price of the C ...

Core Viewpoint - A securities class action lawsuit has been filed against Sable Offshore Corp. for failing to disclose material information during the class period, which has led to a decline in the company's stock price [3][4]. Group 1: Lawsuit Details - Investors who purchased Sable Offshore securities between May 19, 2025, and June 3, 2025, or through the company's secondary public offering on May 21, 2025, have until September 26, 2025, to file lead plaintiff applications [1]. - The lawsuit is pending in the United States District Court for the Central District of California, under the case name Johnson v. Sable Offshore Corp., et al., No. 25-cv-6869 [5]. Group 2: Impact on Stock Price - Following the disclosure of a temporary restraining order that prohibits Sable Offshore from restarting oil transportation through the Las Flores Pipeline System, the company's stock price fell by $0.94, or 3.91%, closing at $23.10 on June 4, 2025 [4]. Group 3: Legal Representation - Kahn Swick & Foti, LLC, a prominent securities litigation law firm, is representing the investors in this case. The firm has been recognized among the top 10 firms nationally based on total settlement value [5].

Core Viewpoint - A class action lawsuit has been filed against Sable Offshore Corp. for allegedly making false and misleading statements regarding its oil production activities off the coast of California during the specified Class Period [1][2]. Group 1: Lawsuit Details - The lawsuit covers purchasers of Sable Offshore Corp. securities between May 19, 2025, and June 3, 2025, and those involved in the company's secondary public offering on May 21, 2025 [1]. - Defendants are accused of falsely claiming that Sable Offshore Corp. had restarted oil production when it had not, leading to materially false and misleading statements about the company's business and prospects [2]. Group 2: Legal Representation - Wolf Haldenstein Adler Freeman & Herz LLP, a law firm with over 125 years of experience in securities litigation, is representing the investors in this case [4]. - The firm encourages affected investors to join the lawsuit and provide any information that may assist in the investigation [5].

If you purchased or acquired securities in Flywire between February 28, 2024 and February 25, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Flywire Corporation ("Flywire" or the "Company") (NASDAQ:FLYW) in the United States ...